Skip to content

To study efficacy of joshanda(Darchini, Saleekha, Saad, Qaranfal, Bisbasa) in the patients of Benign Prostatic Hyperplasia

Clinical study to validate the safety and efficacy of joshanda ( Darchini, Saleekha, Saad, Bisbasa and Qaranfal) in the management of Warm-e-Ghudda-e-Mazi (Benign Prostatic Hyperplasia): An open label, randomized, standard control study . - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/083780
Enrollment
52
Registered
2025-04-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Decoction (joshanda) : All the herbs ( Darchini , Saleekha , Saad , Qaranfal and Bisbasa) will be given to the patient in crude form with the total dosage of 24 gms . Then patient will

Sponsors

Central Council for Research in Unani Medicine New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A diagnosed case of BPH (Warm-e- Ghudda-e- Mazi) that meets the following criteria; 1. Males in the age range of 40 -79 years. 2. Patient expressing concerns about hesitation, frequency and urgency of urination. 3. Patients with a serum PSA level of 4 to 10 ng/ml.

Exclusion criteria

Exclusion criteria: 1. Patients under the age of 40 and older than 79 years. 2. Patients that are mentally disturbed. 3. Refusal to provide consents by patients. 4. Known case of Hypertension, CHD, CKD, liver disease and uncontrolled diabetes. 5. PSA levels over 10ng/ml, suspecting carcinoma 6. Complete urine retention.

Design outcomes

Primary

MeasureTime frame
Serum PSA USG (prostate specific)Timepoint: Serum PSA on day 0 and day 91 USG (prostate specific) on day 0 and day 91

Secondary

MeasureTime frame
Improvement in IPSS (international prostate symptom score) Arbitary scale Improvement in QOL ( Quality of life)Timepoint: IPSS on Day 0 and Day 91 BPH related Arbitary scale at Day 0, 15th ,30th ,45th, 60th ,75th, 91st QOL at Day 0 and 91

Countries

India

Contacts

Public ContactFarhaan Yaqoob

Regional Research Institute of Unani Medicine Srinagar

shameem.rather.sr@gmail.com7889584083

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026